Table 3.
Ranking results of all comparisons.
| Ranks | ADT | ADT + APA | ADT + AAP | ADT + DOC | ADT + ENZ | ADT + RT | |
|---|---|---|---|---|---|---|---|
| OS [HR (95%CI)] | Rank 1 | 0 | 10.36 | 11.00 | 0.06 | 78.58 | 0 |
| Rank 2 | 0 | 30.35 | 55.74 | 1.08 | 12.83 | 0 | |
| Rank 3 | 0 | 42.25 | 32.25 | 18.59 | 6.84 | 0.07 | |
| Rank 4 | 0.09 | 30.94 | 1.01 | 79.52 | 1.66 | 1.78 | |
| Rank 5 | 27.79 | 0.09 | 0 | 0.75 | 0.07 | 70.50 | |
| Rank 6 | 72.12 | 0.02 | 0 | 0 | 0.02 | 27.65 | |
| PSA-PFS | Rank 1 | 0 | 83.17 | 12.17 | 0 | 4.66 | 0 |
| Rank 2 | 0 | 14.05 | 67.18 | 0 | 18.77 | 0 | |
| Rank 3 | 0 | 2.79 | 20.65 | 0.01 | 76.55 | 0 | |
| Rank 4 | 0 | 0 | 0 | 94.2 | 0.01 | 5.84 | |
| Rank 5 | 9.97 | 0 | 0 | 5.83 | 0 | 84.20 | |
| Rank 6 | 90.03 | 0 | 0 | 0.01 | 0 | 9.96 | |
| Time to SSE | Rank 1 | 0.62 | 14.56 | 16.54 | NA | 68.28 | NA |
| Rank 2 | 8.06 | 31.58 | 40.50 | NA | 19.86 | NA | |
| Rank 3 | 34.18 | 30.55 | 27.72 | NA | 7.55 | NA | |
| Rank 4 | 57.14 | 23.30 | 15.24 | NA | 4.31 | NA | |
| Time to pain progression | Rank 1 | 0 | 18.74 | 79.90 | NA | 0.136 | NA |
| Rank 2 | 0.93 | 56.61 | 18.60 | NA | 23.86 | NA | |
| Rank 3 | 17.25 | 18.96 | 1.48 | NA | 62.31 | NA | |
| Rank 4 | 81.82 | 5.69 | 0.02 | NA | 12.47 | NA | |
| Time to chemotherapy | Rank 1 | 0 | 89.31 | 10.69 | NA | NA | NA |
| Rank 2 | 0 | 10.69 | 89.31 | NA | NA | NA | |
| Rank 3 | 1 | 0 | 0 | NA | NA | NA | |
| Low-volume | Rank 1 | 0 | 14.25 | 4.23 | 0.23 | 78.90 | 2.38 |
| Rank 2 | 0 | 30 | 22.1 | 4.27 | 15.25 | 28.37 | |
| Rank 3 | 0.04 | 16.03 | 26.08 | 15.18 | 3.84 | 38.83 | |
| Rank 4 | 1.42 | 14.74 | 24.04 | 34.76 | 1.39 | 23.65 | |
| Rank 5 | 20.20 | 13.27 | 17.62 | 41.64 | 0.55 | 6.72 | |
| Rank 6 | 78.34 | 11.71 | 5.92 | 3.91 | 0.07 | 0.05 | |
| High-volume | Rank 1 | 0 | 28.25 | 62.28 | 4.26 | 5.21 | 0 |
| Rank 2 | 0 | 32.63 | 29.84 | 25.32 | 12.21 | 0 | |
| Rank 3 | 0.04 | 23.41 | 6.71 | 47.88 | 21.90 | 0.06 | |
| Rank 4 | 6.60 | 14.81 | 1.16 | 22.52 | 52.12 | 2.78 | |
| Rank 5 | 75.63 | 0.61 | 0 | 0.01 | 4.72 | 19.03 | |
| Rank 6 | 17.73 | 0.29 | 0 | 0 | 3.84 | 78.13 | |
| GS<8 | Rank 1 | 0 | 21.64 | 56.04 | 2.32 | 20 | 0 |
| Rank 2 | 0.01 | 37.65 | 17.40 | 14.07 | 30.80 | 0.07 | |
| Rank 3 | 0.51 | 26.32 | 10.88 | 37.46 | 24.22 | 0.61 | |
| Rank 4 | 10.67 | 12.52 | 8.95 | 44.90 | 18.08 | 4.88 | |
| Rank 5 | 69.81 | 1.22 | 2.58 | 1.10 | 3.58 | 21.71 | |
| Rank 6 | 19 | 0.65 | 4.15 | 0.14 | 3.32 | 72.73 | |
| GS≥8 | Rank 1 | 0.03 | 23.79 | 32.98 | 7.79 | 29.79 | 5.63 |
| Rank 2 | 0.47 | 20.90 | 27.06 | 19.65 | 22.89 | 9.02 | |
| Rank 3 | 3.45 | 18.27 | 18.03 | 29.14 | 17.72 | 13.39 | |
| Rank 4 | 14.80 | 15.73 | 10.73 | 26.95 | 13.14 | 18.66 | |
| Rank 5 | 37.26 | 10.32 | 6.02 | 12.07 | 8.39 | 25.95 | |
| Rank 6 | 43.99 | 11.00 | 5.18 | 4.41 | 8.07 | 27.36 |
OS, Overall survival; HR, hazard ratio; 95%CI, 95% confidence intervals; PSA-PFS, prostate specific antigen progression-free survival; GS, Gleason score; ADT, androgen deprivation therapy; APA, apalutamide; AAP, abiraterone and prednisolone; DOC, docetaxel; ENZ, enzalutamide; RT, radiotherapy; NA, not available.